Ventripoint Issues Shares for Debt Settlement and Awards Option Grants

Core Viewpoint - Ventripoint Diagnostics Ltd. has received approval from the TSX Venture Exchange to issue 4,276,964 common shares to settle $427,696.35 of debt, aiming to preserve cash for business development [1][2]. Financial Actions - The shares were issued at a price of $0.10 per share and are subject to a hold period of four months and one day [2]. - The company has granted 2,516,500 options to various stakeholders with an exercise price of $0.12, vesting over a period of up to three years [3]. - A total of 780,000 options were exercised recently at a weighted average price of approximately $0.105 per share, generating gross proceeds of $81,800 [4]. Incentives and Future Grants - The annual option grants are designed to incentivize stakeholders to enhance the company's value [4]. - Currently, there are 16,683,500 option grants outstanding with exercise prices ranging from $0.10 to $0.50, and 14,555,167 of these options have vested [4]. - The company has approximately 2.0 million options available for future grants under its Stock Option Plan [5]. Industry Position - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS products providing accurate cardiac measurements comparable to MRI [7]. - The technology is designed to be an affordable alternative, enhancing cardiologists' confidence in patient management and is compatible with all ultrasound systems [7].